RxDoctor Payments Data

Hector Soto, MD

Cardiovascular Disease · Edinburg, TXNPI 1386690360

Payments from drug & device makers

$9,574in general payments, 2019–2025

Across 113 payments — averaging $84.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$3K
  • Medtronic$2K
  • Abbott$2K
  • Cvrx, Inc.$244
  • Novo Nordisk$228
  • Impulse Dynamics (USA) Inc.$178
  • plus $1K from 13 others

What the payments were for

  • Speaking & faculty fees$3,30034%
  • Travel & lodging$2,26524%
  • Food & beverage$4,01042%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,574 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$97,105
Medicare patients
517
Services billed
1,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten25$177,349
XareltoRivaroxaban95$115,544
EliquisApixaban77$94,495
EntrestoSacubitril/Valsartan62$94,373
JardianceEmpagliflozin33$37,002
FarxigaDapagliflozin Propanediol18$23,846
Metoprolol Succinate323$5,091
Nebivolol Hcl40$3,778
Atorvastatin Calcium298$2,953
Rosuvastatin Calcium192$2,402
ClopidogrelClopidogrel Bisulfate193$2,295
Icosapent Ethyl12$2,223
Ranolazine ErRanolazine22$2,164
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med36$2,135
Nifedipine ErNifedipine62$1,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$139$177,34925 claims
Johnson & JohnsonXarelto$55$115,54495 claims
PfizerEliquis$150$94,49577 claims
Boehringer IngelheimJardiance$112$37,00233 claims
AstraZenecaFarxiga$69$23,84618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →